Frank Mottola

Frank Mottola, listed as senior executive, appears in our data through filings on Supernus Pharmaceuticals, Inc. shares, published by SEC (Form 4). We count 21 filings; the first trade dates from 16 February 2023 and the latest from 12 August 2026.

Sales make up the whole of the open-market record (1 sale, €160k). The rest of the record consists of 8 share grants and 12 option exercises.

The latest filing, published on 14 August 2026, reports an option exercise in Supernus Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.